Daily Health Headlines

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

👤by HealthDay 0 comments 🕔Tuesday, October 13th, 2015

MONDAY, Oct. 12, 2015 (HealthDay News) -- Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says.

"What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release.

The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver.

The study showed HIV-positive men on HIV therapy who had no detectable virus in their blood were 80 percent less likely to be infected with hepatitis B over about 9.5 years, compared to men with HIV who weren't on HIV therapy or had detectable levels of the virus in their blood.

Researchers said their findings also confirm the longstanding belief that vaccination against the hepatitis B virus protects people regardless of their HIV status.

Study lead author Dr. Oluwaseun Falade-Nwulia, an assistant professor of medicine at Hopkins, said, "We found a 70 percent reduction in new [hepatitis B] infections in the men who reported receiving at least one dose of [hepatitis B] vaccine."

However, "vaccination rates, even in high-risk individuals, such as men who have sex with men, remain low, and we need to do a better job of encouraging vaccination," she said in the news release.

Adults getting the hepatitis B vaccine should receive three doses within six months, the U.S. Centers for Disease Control and Prevention recommends.

In 1984, when the study began, 41 percent of men with HIV had been vaccinated against hepatitis B, compared with 28 percent of men without HIV, researchers said.

By 2013, the proportion of men who received more than one dose of hepatitis B vaccine increased 67 percent among men with HIV, compared to 58 percent among men who did not have the virus.

Despite the protective effects of HIV therapy, better hepatitis B prevention in gay and bisexual men is needed to control the epidemic of the virus among this population, the study's authors cautioned.

In the United States, gay and bisexual men account for roughly 15 to 25 percent of new hepatitis B infections, the researchers said.

Drug users who share needles are also at risk for the liver disease, according to the CDC.

-- Mary Elizabeth Dallas

Article Credits / Source

HealthDay

HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCE: Johns Hopkins University School of Medicine, news release, Oct. 12, 2015

View More Articles From HealthDay 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More HIV Articles

Drug Combo Shows Early Promise for Remission of HIV

Drug Combo Shows Early Promise for Remission of HIV0

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission in people living with the virus, a new report says. The goal: to free patients from the need ...

Antibodies May Hold Key to HIV Suppression

Antibodies May Hold Key to HIV Suppression0

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions ...

Experimental Medicine Might Rescue People With Drug-Resistant HIV

Experimental Medicine Might Rescue People With Drug-Resistant HIV0

FRIDAY, Oct. 28, 2016 (HealthDay News) -- Researchers report that a new medication might revolutionize the treatment of HIV patients who don't respond to existing drugs. The intravenous drug, known as ibalizumab, is given every two weeks. It's ...

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already ...

HIV May Hide in Tissues, Even After Treatment

HIV May Hide in Tissues, Even After Treatment0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV ...

View More HIV Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!